### **Overview** Unichem Laboratories Ltd is an **international, integrated specialty pharmaceutical company** focused on the development, manufacturing, and marketing of **branded and generic formulations** globally. With core competencies in **complex active pharmaceutical ingredient (API) synthesis, dosage form manufacturing, and advanced R&D**, Unichem serves regulated and emerging markets across North America, South America, Africa, Europe, and Asia-Pacific. Since becoming part of the **Ipca Laboratories Limited group**—a global leader in API manufacturing—Unichem has strengthened its cost competitiveness, product portfolio, and strategic positioning in the global generics landscape. --- ### **Strategic Positioning & Business Model** - **Vertical Integration & Backward Integration**: Unichem operates a vertically integrated model with internal API, intermediate, and formulation capabilities. It has reduced reliance on external API suppliers through capacity expansion at its manufacturing facilities in **Kolhapur, Roha, and Pithampur**, selling its stake in Optimus Drugs Pvt. Ltd. post-capacity buildout. This shift underscores a strategic emphasis on **self-reliance and supply chain resilience**. - **Parent Group Advantage**: As part of **Ipca Laboratories (established in 1949)**, Unichem benefits from: - Cost-competitive API supply - Shared regulatory and technical expertise - Combined market access and scale - Synergy in R&D, manufacturing, and regulatory filings - Reliable related-party transactions enhancing supply assurance and revenue stability - **Global Market Reach**: - Exports to over **120 countries**, with significant presence in **regulated markets (U.S., EU, Canada)** and **high-growth emerging markets (Brazil, South Africa, APAC)**. - The **U.S. is the largest market**, contributing **~57% of revenue**, followed by Brazil and Africa. - U.S. generics market represents ~40% of global generics sales, offering scale but marked by pricing pressure and regulatory scrutiny. --- ### **Research & Development (R&D)** Unichem’s R&D is a cornerstone of its competitive advantage, centered at its **Centre of Excellence in Goa**, which houses: - **Over 300 scientists**, including **30+ PhDs** - Labs for **API process research, formulation development, analytical R&D, clinical research, and IP management** - Capabilities in **tablet, capsule, liquid oral, and injectable dosage forms**, including QbD-compliant ANDA development #### **Key Focus Areas**: - Development of **patent-non-infringing API processes** - **Reverse engineering** and **cost rationalization** - **Novel Drug Delivery Systems (NDDS)** - **Biosimilars** via Recombinant DNA technology (Bio-Tech facility) - Regulatory dossier preparation (ANDAs, DMFs, CEPs) in **U.S., EU, Canada, China, and emerging markets** #### **R&D Output (Recent Highlights)**: | Period | ANDA Approvals | Product Launches (U.S.) | Other Launches | Filings (ANDA/DMF/Dossier) | |---------------|----------------|--------------------------|----------------|----------------------------| | Jul 2025 | 4 | 4 | 2 (South Africa) | 2 ANDAs + 11 emerging mkt | | Jul 2024 | 2 | 4 (U.S.) | 2 (South Africa) | 3 ANDAs, 1 DMF (U.S.) | | Aug 2023 | 5 | 4 (U.S.) | 2 (South Africa) | Submissions in Brazil | | Jul 2022 | 5 | 5 (U.S.) + 2 (Brazil) | – | 6 dossiers (emerging) | | Jul 2021 | **9** (record) | 8 (U.S.) + 2 (Brazil) | – | 5 ANDAs, 2 DMFs, 1 CEP | > **Cumulative R&D Milestone (as of 2025):** Over **75 ANDAs** and **77 DMFs** developed across multiple markets and therapeutic areas. --- ### **Manufacturing Excellence** Unichem operates **state-of-the-art, globally compliant manufacturing facilities** with approvals from **USFDA, MHRA (UK), EMA, Health Canada, PMDA (Japan), and WHO-GMP**. Key sites include: - **Goa (Units 1 & 2)** – Formulations and APIs; commercial production began for Unit-2 in 2022–23 - **Ghaziabad** – Formulations (e.g., Depakote ER, Guanfacine) - **Baddi** – Supplies primarily to Africa, CIS, and Asian markets (90% of output) - **API Plants** – Located in **Kolhapur, Roha, Pithampur**; primarily captive use Environmental, Health & Safety (EHS) upgrades include **Multi Effect Evaporators and Reverse Osmosis systems**, enhancing sustainability. --- ### **Regulatory Approvals & Product Portfolio** Unichem has a consistent track record of **USFDA and global regulatory approvals**, particularly in the U.S. market where it targets high-growth therapeutic segments: - **Cardiovascular** (Prasugrel, Atenolol/Chlorthalidone) - **CNS / Neurology** (Zonisamide, Divalproex ER, Carbamazepine) - **Metabolic** (Metformin XR, Sitagliptin, Ranolazine) - **Pain & Inflammation** (Celecoxib) - **Gastroenterology, Anti-infectives, Urology (Tolterodine), Dermatology (Apremilast)** #### **Recent Product Approvals (2020–2023)**: | Product (Generic) | Brand Equivalent | Indication | Approval Date | Manufacturing Site | |----------------------------------------|----------------------|-------------------------------------------|---------------|--------------------| | **Divalproex ER Tablets** | Depakote ER (AbbVie) | Bipolar, migraines | Feb 2022 | Goa | | **Carbamazepine Tablets** | Tegretol (Novartis) | Seizures, neuralgia | Aug 2022 | Goa | | **Ranolazine ER Tablets** | Ranexa (Gilead) | Chronic angina | Mar 2023 | Goa | | **Prasugrel Tablets** | Effient (Daiichi) | Acute coronary syndrome | Aug 2023 | Goa | | **Sitagliptin Tablets** (tentative) | Januvia (Merck) | Type 2 diabetes | Jul 2021 | Goa | | **Celecoxib Capsules** | Celebrex (Pfizer) | Arthritis, pain | Jan 2021 | Goa | | **Apremilast Tablets** | Otezla (Amgen) | Plaque psoriasis | Feb 2021 | – | --- ### **Growth Strategy (2024–2025 Outlook)** 1. **Portfolio Expansion**: Focused on **complex generics, value-added formulations, and NDDS**, improving margins and reducing competition intensity. 2. **Regulatory Acceleration**: Investing in **regulatory science, dossier development, and digital compliance tools** (e.g., digitized SOPs, virtual audits) to speed up approvals in the U.S., EU, and emerging markets. 3. **Market Expansion**: - **U.S.**: Strategic expansion in CNS, cardiovascular, anti-infectives, GI - **Brazil**: Growing at **>9% CAGR**; focus on regulatory alignment with ANVISA and strategic alliances - **APAC & Africa**: Targeting rising healthcare demand via ACASIA division 4. **India’s PLI Scheme Leverage**: Government’s **₹15,000 crore PLI scheme** supports domestic API manufacturing; Unichem plans to invest in **new capacities and capabilities** to reduce import dependence. 5. **R&D & Innovation**: - Increased filings anticipated across **U.S. and emerging markets** - Focus on **biosimilars, enzyme technology, and green chemistry** for cost and environmental benefits - **Out-licensing potential** in generics and biologics --- ### **Leadership & Governance** - **Dr. Prakash A. Mody** was major shareholder (46.16%) pre-2023; reduced to **12.78%** post-Share Purchase Agreement (SPA), indicating ownership restructuring aligned with strategic integration with Ipca. - **Mr. Milind Kunkolienkar (Director Technical)** brings 40+ years of experience in manufacturing, R&D, and regulatory compliance. ---